Abstract Number: 2317 • 2016 ACR/ARHP Annual Meeting
Preliminary Validation of a Magnetic Resonance Imaging-Based Inflammatory Scoring System in Adult Myositis
Background/Purpose: in patients with active myositis, magnetic resonance imaging (MRI) often demonstrates muscle edema thought to represent active inflammation. An MRI-based muscle inflammatory scoring system…Abstract Number: 2323 • 2016 ACR/ARHP Annual Meeting
Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis
Background/Purpose: In order to enable meaningful clinical care and research, accurate algorithms are needed to identify patients with dermatomyositis (DM). In this study, we aimed…Abstract Number: 274 • 2016 ACR/ARHP Annual Meeting
Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.
Background/Purpose: Anti- melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (DM) and clinically amyopathic DM (CADM) often develop rapidly progressive interstitial lung disesase (RP-ILD),…Abstract Number: 2328 • 2016 ACR/ARHP Annual Meeting
Serum Ferritin Levels, Distribution of Ground Glass Opacities and New Development of Lung Infiltration during Therapy Predict Prognosis of Interstitial Lung Disease in Anti-MDA5 Ab Positive Dermatomyositis
Background/Purpose: Anti-MDA5 Ab positive dermatomyositis (DM) is a unique subset of inflammatory myopathy characterized by non- or mild muscle weakness, skin manifestation such as…Abstract Number: 275 • 2016 ACR/ARHP Annual Meeting
In Vitro Activation of Type I Interferon Pathway Reproduces the Characteristics Damages Observed in Dermatomyositis Patients
Background/Purpose: The type I interferons (IFN-I) including IFN-a, and IFN-b are key cytokines involved in innate immune response to viral infection. Almost all cells can…Abstract Number: 285 • 2016 ACR/ARHP Annual Meeting
Antibodies to Small Ubiquitin-like Modifier Activating Enzyme: Frequency and Characteristics of Antibody-Positive Patients in an Unselected Cohort
Background/Purpose: Antibodies to small ubiquitin-like modifier activating enzyme (SAE) are associated with diagnosis of dermatomyositis (DM). The aims of this study were to establish the…Abstract Number: 286 • 2016 ACR/ARHP Annual Meeting
Clinical Significance and Prognostic Value of Neutrophil to Lymphocyte Ratio in Patients with Dermatomyositis
Background/Purpose: Recent studies have suggested that neutrophil to lymphocyte ratio (NLR) could be an emerging predictive marker of disease activity or mortality in patients with…Abstract Number: 1187 • 2016 ACR/ARHP Annual Meeting
Ultraviolet Radiation Exposures Are Associated with Dermatomyositis in a National Myositis Registry
Background/Purpose: Previous studies suggest exposure to ultraviolet (UV) radiation may be a risk factor for dermatomyositis (DM) and autoantibody phenotypes, based on differences in prevalence…Abstract Number: 1237 • 2016 ACR/ARHP Annual Meeting
The Economic Burden of Dermatomyositis and Polymyositis in the US
Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are inflammatory myopathies that can lead to persistent muscle weakness and disability. Although significant healthcare resource utilization (HCRU) and work…Abstract Number: 1290 • 2016 ACR/ARHP Annual Meeting
The Usefulness of Volumetric Parameters of FDG PET/CT for Reflecting Disease Activity in Polymyositis/Dermatomyositis Patients
Background/Purpose: Polymyositis/dermatomyositis (PM/DM) are systemic inflammatory disorders predominantly affecting skeletal muscles and skin respectively. Although muscle biopsy is the most important to the diagnosis of…Abstract Number: 1368 • 2016 ACR/ARHP Annual Meeting
Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of the skin and striated muscle. A subset of patients can present with rash only, labeled…Abstract Number: 1154 • 2015 ACR/ARHP Annual Meeting
Ajulemic Acid Is a Novel Cannabinoid That Suppresses the Secretion of TNF-α and IFN-α from the Peripheral Blood Mononuclear Cells of DM Patients In Vitro
Background/Purpose: DM is an autoimmune disease with cutaneous symptoms often accompanied by inflammatory muscle and/or lung disease. Current therapies for DM are often toxic and…Abstract Number: 1885 • 2015 ACR/ARHP Annual Meeting
Identification and Clinical Correlations of Rare Autoantibodies in Systemic Sclerosis and Poly/Dermatomyositis Patients
Background/Purpose: Systemic Sclerosis (SSc), Polymyositis (PM) and Dermatomyositis (DM) are characterized by the presence of serum autoantibodies (autoAbs) which are central in the diagnosis, predicting…Abstract Number: 2363 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Adrenocorticotropic Hormone Gel (Acthar Gel ®) in Refractory Dermatomyositis or Polymyositis
Background/Purpose: Adrenocorticotropic hormone (ACTH) gel (repository corticotropin injection) is a long-acting full sequence ACTH that may include other pro-opiomelanocortin peptides thought to have anti-inflammatory and…Abstract Number: 2369 • 2015 ACR/ARHP Annual Meeting
Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: A Longitudinal Analysis
Background/Purpose: Dermatomyositis (DM) patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are at increased risk of developing interstitial lung disease (ILD). The natural history of…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- 24
- Next Page »